A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis- acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 5, 1999, Pages 385-388

  DeMario, Mark D ^a   Ratain, Mark J ^b   Vogelzang, Nicholas J ^a   Mani, Sridhar ^a   Vokes, Everett E ^a   Fleming, Gini F ^a   Melton, Kimberly ^a   Johnson, Sheryl ^a   Benner, Steven ^c   Lebwohl, David ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Advanced cancer; Hyperemesis; JM 216; Oral chemotherapy; UFT

Indexed keywords

FOLINIC ACID; ONDANSETRON; PROCHLORPERAZINE; SATRAPLATIN; UFT;

ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG FORMULATION; DRUG SAFETY; FATIGUE; HUMAN; LIVER TOXICITY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TOXICITY TESTING; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HUMANS; LEUCOVORIN; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; TEGAFUR; TREATMENT OUTCOME; URACIL; VOMITING;

EID: 0033031323     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050911     Document Type: Article

References (14)

1. Au JL, Sadee W (1980) Activation of ftorafur to 5-fluorouracil and gamma-butyrolactone. Cancer Res 40: 2814
2. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlates with response to platinum-based chemotherapy. J Clin Invest 94: 703
3. Esaki T, Nakano S, Matsumoto N, Fujishim H, Niho Y (1996) Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous cell carcinoma cell line. Int J Cancer 65: 479
4. Groen HJM, Smit EF, Bauer J, Calvert AH, Weil C, Crabeels D, Schacter LP, Smith I (1996) A phase II study of oral platinum JM-216 as first-line treatment in small cell lung cancer (abstract). Proc Am Soc Clin Oncol 15: 1128
5. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer B (1995) A phase I and pharmacology study of an oral platinum complex, JM-216: dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 36: 451
6. McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabarabara P, Harrap KR, Judson IR (1997) Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15: 2691
7. Meropol NJ, Rustum YM, Petrelli NJ, Rodriguez-Bigas M, Frank C, Ho DH, Kurowski M, Creaven PJ (1996) A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 37: 581
8. Ota K, Taguchi T, Kimura K (1988) Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 333
9. Pagani O, Bauer J, Bomer M (1996) Phase I study of the oral platinum derivative JM-216 given daily for 14 days. 21st Congress ESMO, Vienna, 1-5 November
10. Pazdur R, Rivera E, Diaz-Canton E, Lassere Y, Bready B, Winn R, Ajani J (1995) Phase I trial of UFT (uracil-tegafur) with leucovin: a 14 day schedule (abstract). Proc Am Soc Clin Oncol 14: 1568a
11. Peereboom DM, Wood L, Connell C, Spisak J, Smith D, Liebwohl D, Bukowski RM (1997) Phase II trial of oral BMS-182751 (JM-216) in hormone refractory prostate cancer (HRPC)(abstract). Proc Am Soc Clin Oncol 16: 339a
12. Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CF, Murrer BA, Harrap KR (1996) Biotransformation of the platinum drug JM-216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38: 155
13. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP (1995) A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin: an active oral regimen for advanced colon cancer. Cancer 75: 782
14. Scanlon KJ, Newman EM, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923